Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264082 · ClinicalTrials.gov registry record
Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
A clinical trial, sponsored by University of Louisville.
- Completed
- Registry status
- 30
- Enrollment target
NCT00264082 is a clinical trial that has completed, run by University of Louisville. The registered enrollment target is 30 participants.
The verdict
NCT00264082 has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to breast cancer. Tartrate-resistant acid phosphatase (TRAP) is a protein released into the blood stream as a result of bone destruction caused by metastasis of breast cancer to the bone. Bone destruction causes pain and bone fractures. This study will measure TRAP levels in serum taken from breast cancer patients to see if TRAP levels will be able to predict the effect of Zometa® treatment on bone destruction, pain and bone fractures.
Interventions
- DRUG Zometa(drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264082
The ClinicalTrials.gov registry entry for NCT00264082 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zometa(drug) is the first listed.
NCT00264082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264082 about?
NCT00264082 is a clinical study titled "Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis". The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to breast cancer. Tartrate-resistant acid phosphatase (TRAP) is a protein ...
What is the current status of trial NCT00264082?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2004-09.
What interventions are being tested in trial NCT00264082?
The interventions under investigation include: Zometa(drug) (DRUG).
Who is sponsoring clinical trial NCT00264082?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.